Certara launches Cardiac Safety Simulator to determine arrhythmia risk for drug candidates

Based on an in-silico model of human ventricular heart cells, Certara’s Cardiac Safety Simulator (CSS) helps sponsors to assess arrhythmia risk before a new drug candidate enters clinical trials and determine safe drug doses for specific patient populations.